MedTrace Logo

Evaluation of Carboplatin/Paclitaxel/Bevacizumab in the Treatment of Advanced Stage Endometrial Carcinoma

NCT00513786 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 38

Last updated 2025-03-28

Study results available
· View outcomes & findings →

Summary

Purpose of this study is to determine the effectiveness of the drug combination carboplatin, paclitaxel, and bevacizumab(Avastin) in patients with advanced stage endometrial carcinoma.

Conditions

Interventions

DRUG

Carboplatin

AUC (area under curve) 5 Intervenous (IV) over 30 minutes given every 21 days for a maximum of 6 cycles.

DRUG

Paclitaxel

175 mg/m2 over 3 hours given every 21 days for a maximum of 6 cycles.

DRUG

bevacizumab

15 mg/kg intervenous (IV) given every 21 days for a maximum of 6 cycles.

Sponsors & Collaborators

  • Genentech, Inc.

    collaborator INDUSTRY

  • David O'Malley

    lead OTHER

Principal Investigators

  • David O'Malley, MD · The Ohio State University Division of Gyn Oncology

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-08-01
Primary Completion
2017-01-03
Completion
2017-01-03
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00513786 on ClinicalTrials.gov